Suppr超能文献

影响利福平耐药/耐多药结核病患者长期治疗方案不良转归的因素。

Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen.

机构信息

University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Türkiye.

Chest Disease, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye.

出版信息

Int J Mycobacteriol. 2024 Jul 1;13(3):265-274. doi: 10.4103/ijmy.ijmy_132_24. Epub 2024 Sep 14.

Abstract

BACKGROUND

Drug-resistant tuberculosis (DR-TB) poses a significant threat to global TB control and remains a major public health issue. This study aims to evaluate treatment outcomes and identify risk factors for unfavorable outcomes in patients with multi-DR-TB (MDR-TB) treated at a major reference hospital in Istanbul.

METHODS

We conducted a retrospective analysis of 413 patients with rifampicin-resistant and MDR-TB who received treatment between January 1, 2013, and December 31, 2023, at the University of Health Sciences Süreyyapaşa Chest Diseases Training and Research Hospital. Patients were treated following the World Health Organization and national guidelines, with regimens tailored to individual drug resistance profiles and side effect management. Demographic data, comorbidities, microbiological follow-up, drug resistance patterns, treatment regimens, and radiological findings were analyzed.

RESULTS

Treatment success was achieved in 350 patients (84.74%). Thirty-two patients (7.74%) were lost to follow-up, and 32 patients (7.74%) died. Logistic regression analysis identified several factors associated with unfavorable treatment outcomes: comorbidities (odds ratio [OR]: 7.555, P = 0.001), quinolone resistance (OR: 3.695, P = 0.030), and bronchiectasis (OR: 4.126, P = 0.013). Additional significant factors included male gender (P = 0.007), foreign-born status (P = 0.013), age over 35 years (P = 0.002), previous treatment history (P = 0.058), and drug side effects (P = 0.012).

CONCLUSION

The long-term regimen for MDR-TB was found to be highly successful, with an 84.74% treatment success rate. Effective treatment regimens, close patient follow-up, early recognition of side effects, and comprehensive management are crucial for achieving successful outcomes. Identifying and addressing risk factors such as comorbidities, drug resistance, and specific patient demographics can further improve treatment success rates. This study underscores the importance of tailored treatment strategies and robust patient management in combating MDR-TB.

摘要

背景

耐多药结核病(DR-TB)对全球结核病控制构成重大威胁,仍然是一个主要的公共卫生问题。本研究旨在评估在伊斯坦布尔一家主要参考医院接受治疗的多耐药结核病(MDR-TB)患者的治疗结果,并确定不良结局的风险因素。

方法

我们对 2013 年 1 月 1 日至 2023 年 12 月 31 日期间在卫生科学大学苏雷亚帕萨胸部疾病培训和研究医院接受治疗的 413 例利福平耐药和 MDR-TB 患者进行了回顾性分析。患者按照世界卫生组织和国家指南进行治疗,根据个体药物耐药谱和副作用管理情况制定治疗方案。分析了人口统计学数据、合并症、微生物学随访、耐药模式、治疗方案和影像学发现。

结果

350 例(84.74%)患者治疗成功。32 例(7.74%)患者失访,32 例(7.74%)患者死亡。Logistic 回归分析确定了与不良治疗结局相关的几个因素:合并症(比值比[OR]:7.555,P=0.001)、喹诺酮类耐药(OR:3.695,P=0.030)和支气管扩张(OR:4.126,P=0.013)。其他重要因素包括男性(P=0.007)、外国出生(P=0.013)、年龄大于 35 岁(P=0.002)、既往治疗史(P=0.058)和药物副作用(P=0.012)。

结论

MDR-TB 的长期方案治疗成功率很高,治疗成功率为 84.74%。有效的治疗方案、密切的患者随访、早期识别副作用以及综合管理对于获得成功的结果至关重要。确定和解决合并症、耐药性和特定患者人口统计学等风险因素可以进一步提高治疗成功率。本研究强调了制定个体化治疗策略和强化患者管理在抗击 MDR-TB 中的重要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验